Pilot Investigation of Social and Environmental Risk Factors for Incidence and Outcomes of Multiple Myeloma in The State of Indiana

AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Systemic Therapy

GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Long-Term Adverse Health Outcomes in Survivors of Germ Cell Tumors Treated with High Dose Chemotherapy

The Indiana Myeloma Registry